Subscribe or Manage Preferences
VBCR - December 2015, Volume 4, No 6 - Personalized Medicine in Rheumatology
Rosemary Frei, MSc

The versatile multibiomarker disease activity (MBDA) score may be able to predict rheumatoid arthritis (RA) relapse within the first year of tapering disease-modifying antirheumatic drug (DMARD) treatment.

Data presented in poster format at the 2015 annual meeting of the American College of Rheumatology1 and also published in the Annals of the Rheumatic Diseases2 indicated 58% of patients who relapsed had moderate or high MBDA scores at baseline versus 21% of those who remained in remission.

The analysis was based on outcomes in RETRO, a phase 3, multicenter, randomized, open-label, prospective, controlled, parallel-group study. The patients, who had been in remission for at least 6 months, were randomized to continuation of their existing conventional or biologic DMARD for 1 year, 50% reduction of the DMARD over 1 year, or 50% reduction of the DMARD over the first 6 months before complete cessation of the DMARD.

A multivariate logistic regression analysis indicated that being positive for anticitrullinated protein antibody was a predictor of relapse (OR = 24.47), as were elevated MBDA score (odds ratio [OR] = 8.54), DMARD continuation versus tapering (OR = 5.94), and DMARD continuation versus stopping (OR = 5.41).

References

  1. Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multi-biomarker disease activity (MBDA) and autoantibody status in rheumatoid arthritis patients tapering DMARD treatment. Presented at: 2015 American College of Rheumatology Annual Meeting; November 7-11, 2015; San Francisco, CA. Abstract 2584.
  2. Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2015 Oct 19. Epub ahead of print.
Related Items
Poor Pregnancy Outcomes Seen in Women with Childhood-Onset SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 23, 2016 in Canadian Rheumatology Association Annual Meeting
Addressing Undertreatment of Patients with Gout Using EMR Data
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 11, 2016 in Canadian Rheumatology Association Annual Meeting
Six-Month OBSErve Study Results Indicate Positive Effects of Belimumab in SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 8, 2016 in Canadian Rheumatology Association Annual Meeting
Improvements Needed in Access to Timely Quality Care
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 7, 2016 in Canadian Rheumatology Association Annual Meeting
Orthotics Reduce Foot Pain in Juvenile Idiopathic Arthritis
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 4, 2016 in Juvenile Idiopathic Arthritis
Biosimilar Infliximab Recommended for Approval
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in FDA News & Updates
Early Response to Abatacept Detectable by Sophisticated Ultrasound
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Rheumatoid Arthritis
Updated Recommendations for Pharmacologic Treatment of Patients with Psoriatic Arthritis
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Psoriatic Arthritis
Two Studies Point to Inadequate Evidence Supporting Many FDA Drug Approvals
Rosemary Frei, MSc
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Health Policy
Multidisciplinary Approach or Aerobic Exercise for Fibromyalgia May Not Be Cost-Effective
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Fibromyalgia
Last modified: January 13, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology